VERCYTE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERCYTE is an oral small-molecule tablet approved in 1966 by Abbott. The specific indication and mechanism of action are not documented in available data. This legacy product represents a long-established therapeutic entity in Abbott's portfolio.
LOE Approaching
As LOE approaches, the brand team is likely small and focused on maximizing remaining patent life; expect cost-containment and transition-planning activities rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VERCYTE has zero linked job postings, reflecting its LOE-approaching status and minimal hiring activity. Working on this product offers limited career growth but valuable experience in lifecycle management, generic transition planning, and cost-optimization strategies.
Brand ManagerSales Representative
Worked on VERCYTE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.